Breaking Down the Rationale for Targeting TROP2 in TNBC

In this podcast, experts Filipa Lynce, MD, and Rita Nanda, MD, discuss unmet needs in triple-negative breast cancer (TNBC) and the rationale for using TROP2-targeting antibody-drug conjugates (ADCs) in this disease.